Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Yee Peng PhoonJared E LopesLukas W PfannenstielClaudia Marcela Diaz-MonteroYe F TianMarc S ErnstoffPauline FunchainJennifer S KoRaymond WinquistHeather C LoseyJan Joseph MelenhorstBrian R GastmanPublished in: Journal for immunotherapy of cancer (2024)
Our model reproduces differential effects of immunotherapy in melanoma patients, capturing the inherent heterogeneity in clinical responses. Taken together, these data demonstrate our model's translatability for novel immunotherapies in melanoma patients. The data are also supportive for the continued clinical investigation of nemvaleukin as a novel immunotherapeutic for the treatment of melanoma.